Format
Sort by
Items per page

Send to

Choose Destination

Best matches for IBRUTINIB/AE:

Search results

Items: 1 to 20 of 292

1.

Management of adverse effects/toxicity of ibrutinib.

Paydas S.

Crit Rev Oncol Hematol. 2019 Apr;136:56-63. doi: 10.1016/j.critrevonc.2019.02.001. Epub 2019 Feb 10. Review.

PMID:
30878129
2.

Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.

Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ.

PLoS One. 2019 Feb 20;14(2):e0211228. doi: 10.1371/journal.pone.0211228. eCollection 2019.

3.

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.

Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH.

Lancet Haematol. 2019 Feb;6(2):e100-e109. doi: 10.1016/S2352-3026(18)30216-3.

PMID:
30709431
4.

In brief: Acalabrutinib (Calquence) for mantle cell lymphoma.

[No authors listed]

Med Lett Drugs Ther. 2018 Nov 5;60(1559):e184. No abstract available.

PMID:
30681658
5.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W.

Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.

PMID:
30642819
6.

Acalabrutinib for adults with mantle cell lymphoma.

Jurczak W, Długosz-Danecka M, Wang M.

Expert Rev Clin Pharmacol. 2019 Mar;12(3):179-187. doi: 10.1080/17512433.2019.1568868. Epub 2019 Jan 26. Review.

PMID:
30638402
7.

Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.

Tobinai K, Uchida T, Fukuhara N, Nishikawa T.

Int J Hematol. 2019 Mar;109(3):366-368. doi: 10.1007/s12185-018-02577-8. Epub 2019 Jan 8. No abstract available.

PMID:
30623356
8.

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC.

N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.

PMID:
30501481
9.
10.

Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.

Khan Y, O'Brien S.

Future Oncol. 2019 Feb;15(6):579-589. doi: 10.2217/fon-2018-0637. Epub 2018 Nov 1.

PMID:
30381956
11.

Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR.

Li R, Du Y, Shen J.

SAR QSAR Environ Res. 2018 Nov;29(11):847-873. doi: 10.1080/1062936X.2018.1518927. Epub 2018 Oct 3.

PMID:
30280589
12.

Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice.

Nam HY, Nam JH, Yoon G, Lee JY, Nam Y, Kang HJ, Cho HJ, Kim J, Hoe HS.

J Neuroinflammation. 2018 Sep 19;15(1):271. doi: 10.1186/s12974-018-1308-0.

13.

Novel Approaches in Waldenström Macroglobulinemia.

Spinner MA, Varma G, Advani RH.

Hematol Oncol Clin North Am. 2018 Oct;32(5):875-890. doi: 10.1016/j.hoc.2018.05.014. Epub 2018 Jul 19. Review.

PMID:
30190025
14.

Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation.

Zhang Q, Chen J, Gao H, Zhang S, Zhao C, Zhou C, Wang C, Li Y, Cai Z, Mou L.

Int J Med Sci. 2018 Jul 13;15(11):1118-1128. doi: 10.7150/ijms.24460. eCollection 2018.

15.

New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?

Rule S, Chen RW.

Expert Rev Hematol. 2018 Sep;11(9):749-756. doi: 10.1080/17474086.2018.1506327. Epub 2018 Aug 2. Review.

PMID:
30052472
16.

Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.

Faisal MS, Shaikh H, Khattab A, Albrethsen M, Fazal S.

J Oncol Pharm Pract. 2018 Jul 25:1078155218788717. doi: 10.1177/1078155218788717. [Epub ahead of print]

PMID:
30045683
17.

Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.

Shaikh H, Khattab A, Faisal MS, Chilkulwar A, Albrethsen M, Sadashiv S, Fazal S.

J Oncol Pharm Pract. 2018 Jul 25:1078155218788707. doi: 10.1177/1078155218788707. [Epub ahead of print]

PMID:
30045682
18.

Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy.

Hsiehchen D, Arasaratnam R, Raj K, Froehlich T, Anderson L.

Oncology. 2018;95(5):319-322. doi: 10.1159/000490617. Epub 2018 Jul 25. Review.

PMID:
30045034
19.

Cryptococcus neoformans empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature.

Swan CD, Gottlieb T.

BMJ Case Rep. 2018 Jul 18;2018. pii: bcr-2018-224786. doi: 10.1136/bcr-2018-224786. Review.

PMID:
30021735
20.

A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment.

Suzuki T, Miyakoshi S, Nanba A, Uchiyama T, Kawamoto K, Aoki S.

J Clin Exp Hematop. 2018 Sep 19;58(3):136-140. doi: 10.3960/jslrt.18012. Epub 2018 Jul 14.

Supplemental Content

Loading ...
Support Center